AstraZeneca's (AZN.US) Tagrisso small molecule combination therapy has been approved again.

According to the Zhitong Finance APP, AstraZeneca (AZN.US) announced today that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) combined with pemetrexed and platinum chemotherapy has been approved in the European Union for first-line treatment of advanced epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC) in adult patients who have exon 19 deletion or exon 21 (L858R) mutation. Tagri

Zhitong FinanceJul 6 07:45

Express News | First-line treatment for advanced cancer! The small molecule combination therapy of Astrazeneca has been approved again.

BreakingsJul 6 07:37

What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com

By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon

Barron'sJul 5 23:09

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

Yahoo FinanceJul 5 22:16

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

Zacks Jul 5 21:30

Investors in AstraZeneca (LON:AZN) Have Seen Strong Returns of 115% Over the Past Five Years

Yahoo FinanceJul 5 20:34